YQBS Improves Cognitive Dysfunction in Diabetic Rats: Possible Association with Tyrosine and Tryptophan Metabolism

Objective This study is aimed to determine the metabolomic effects of the hybrid medicine formula Yi-Qi-Bu-Shen (YQBS) on the neurotransmitter aspects of cognitive impairment in diabetic rats. Methods In the current study, streptozotocin (STZ) was used to induce diabetic animal model in male Sprague Dawley (SD) rats. After successful establishment of diabetic SD rats’ model, age-matched healthy SD rats and diabetic SD rats were treated with low and high doses of YQBS, and then tested for learning memory ability and analyzed for pathological changes. In addition, neurotransmitter metabolic changes in hippocampal subdivisions of rats from different treated groups were analyzed using liquid chromatography-mass spectrometry (LC-MS) technique. Results YQBS could significantly improve memory-cognitive impairment in diabetic rats as evidenced by the shortening of latency to target and the reduction of latency first entrance to target. Moreover, YQBS also improved the pathological alterations in the hippocampal region in the brains of diabetic rats. Metabolomic analysis showed that the expression of noradrenaline hydrochloride was down-regulated and the expressions of levodopa and 5-hydroxytryptophan were up-regulated in the hippocampal tissues of diabetic rats treated with YQBS. Conclusion These findings demonstrate that YQBS has protective effects against diabetic cognitive dysfunction, which might act through alteration in tyrosine and tryptophan metabolism.

[1]  C. Colak,et al.  Alpha lipoic acid decreases neuronal damage on brain tissue of STZ-induced diabetic rats , 2022, Physiology & Behavior.

[2]  G. Doblhammer,et al.  Diabetes duration and the risk of dementia: a cohort study based on German health claims data , 2021, Age and Ageing.

[3]  Libin Zhan,et al.  ZiBuPiYin Recipe Prevented and Treated Cognitive Decline in ZDF Rats With Diabetes-Associated Cognitive Decline via Microbiota–Gut–Brain Axis Dialogue , 2021, Frontiers in Cell and Developmental Biology.

[4]  Jun Song,et al.  Effects of Berberine on Diabetes and Cognitive Impairment in an Animal Model: The Mechanisms of Action. , 2021, The American journal of Chinese medicine.

[5]  Di Liu,et al.  Nao-Fu-Cong ameliorates diabetic cognitive dysfunction by inhibition of JNK/CHOP/Bcl2-mediated apoptosis in vivo and in vitro. , 2020, Chinese journal of natural medicines.

[6]  R. Verpillot,et al.  Correlation between cognition and plasma noradrenaline level in Alzheimer’s disease: a potential new blood marker of disease evolution , 2020, Translational Psychiatry.

[7]  A. Sinclair,et al.  Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. , 2020, The lancet. Diabetes & endocrinology.

[8]  R. Gullapalli,et al.  Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons , 2020, International journal of molecular sciences.

[9]  J. Tolstrup,et al.  Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals , 2020, Epidemiology and Psychiatric Sciences.

[10]  M. Delorenzi,et al.  Systemic and central nervous system metabolic alterations in Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[11]  Jiayi Yang,et al.  Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze. , 2019, Journal of visualized experiments : JoVE.

[12]  Ru-yi Zhang,et al.  Berberine Ameliorates Spatial Learning Memory Impairment and Modulates Cholinergic Anti-Inflammatory Pathway in Diabetic Rats , 2019, Front. Pharmacol..

[13]  J. Filosa,et al.  NLRP3 inflammasome inhibition with MCC950 improves diabetes‐mediated cognitive impairment and vasoneuronal remodeling after ischemia , 2019, Pharmacological research.

[14]  K. Narkiewicz,et al.  Cognitive Dysfunction in Type 1 Diabetes Mellitus. , 2019, The Journal of clinical endocrinology and metabolism.

[15]  G. Biessels,et al.  Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications , 2018, Nature Reviews Endocrinology.

[16]  D. Weinshenker.  Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease , 2018, Trends in Neurosciences.

[17]  Shuhu Zhou,et al.  Chrysophanol Relieves Cognition Deficits and Neuronal Loss Through Inhibition of Inflammation in Diabetic Mice , 2018, Neurochemical Research.

[18]  Juan Wang,et al.  Quantitative profiling of neurotransmitter abnormalities in brain, cerebrospinal fluid, and serum of experimental diabetic encephalopathy male rat , 2017, Journal of neuroscience research.

[19]  Lixing Xu,et al.  Paeoniflorin ameliorates cognitive dysfunction via regulating SOCS2/IRS-1 pathway in diabetic rats , 2017, Physiology & Behavior.

[20]  Kalpesh R. Patil,et al.  Challenges and issues with streptozotocin-induced diabetes - A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. , 2016, Chemico-biological interactions.

[21]  P. Nathan,et al.  Levodopa enhances explicit new‐word learning in healthy adults: a preliminary study , 2015, Human psychopharmacology.

[22]  S. Mangia,et al.  Impact of diabetes on cognitive function and brain structure , 2015, Annals of the New York Academy of Sciences.

[23]  M. Garcia-Alloza,et al.  Increased Spontaneous Central Bleeding and Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus , 2015, Molecular Neurobiology.

[24]  Yunjia Chen,et al.  Noradrenergic dysfunction in Alzheimer's disease , 2015, Front. Neurosci..

[25]  F. Liu,et al.  Bu-Shen-Yi-Qi formulae suppress chronic airway inflammation and regulate Th17/Treg imbalance in the murine ovalbumin asthma model. , 2015, Journal of Ethnopharmacology.

[26]  N. Maghsoudi,et al.  Insulin protects against Aβ-induced spatial memory impairment, hippocampal apoptosis and MAPKs signaling disruption , 2014, Neuropharmacology.

[27]  A. K. Datusalia,et al.  Amelioration of Diabetes-induced Cognitive Deficits by GSK-3β Inhibition is Attributed to Modulation of Neurotransmitters and Neuroinflammation , 2014, Molecular Neurobiology.

[28]  Wei Gao,et al.  Neuroprotective effects of the Chinese Yi-Qi-Bu-Shen recipe extract on injury of rat hippocampal neurons induced by hypoxia/reoxygenation. , 2013, Journal of ethnopharmacology.

[29]  H. Braak,et al.  Where, when, and in what form does sporadic Alzheimer's disease begin? , 2012, Current opinion in neurology.

[30]  R. Takayanagi,et al.  Effects of the Chinese Yi-Qi-Bu-Shen Recipe extract on brainstem auditory evoked potential in rats with diabetes. , 2011, Journal of ethnopharmacology.

[31]  X. Mao,et al.  Astragalus polysaccharide improves insulin sensitivity in KKAy mice: regulation of PKB/GLUT4 signaling in skeletal muscle. , 2010, Journal of ethnopharmacology.

[32]  E. van Marck,et al.  In vivo antioxidative activity of a quantified Pueraria lobata root extract. , 2010, Journal of ethnopharmacology.

[33]  X. Mao,et al.  Astragalus polysaccharides alleviates glucose toxicity and restores glucose homeostasis in diabetic states via activation of AMPK , 2009, Acta Pharmacologica Sinica.

[34]  X. Mao,et al.  Astragalus polysaccharide reduces hepatic endoplasmic reticulum stress and restores glucose homeostasis in a diabetic KKAy mouse model , 2007, Acta Pharmacologica Sinica.

[35]  Wei Wei,et al.  Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. , 2006, Journal of ethnopharmacology.

[36]  S. Knecht,et al.  A shift of paradigm: From noradrenergic to dopaminergic modulation of learning? , 2006, Journal of the Neurological Sciences.

[37]  C. Vorhees,et al.  Morris water maze: procedures for assessing spatial and related forms of learning and memory , 2006, Nature Protocols.

[38]  Xiaoxin Yin,et al.  Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. , 2006, Canadian journal of physiology and pharmacology.

[39]  Yong Wu,et al.  Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B , 2005, Acta Pharmacologica Sinica.

[40]  Nathan Herrmann,et al.  The role of norepinephrine in the behavioral and psychological symptoms of dementia. , 2004, The Journal of neuropsychiatry and clinical neurosciences.

[41]  E. Ringelstein,et al.  Levodopa: Faster and better word learning in normal humans , 2004, Annals of neurology.

[42]  Z. Hong,et al.  Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia , 2004, Neuroscience Letters.

[43]  M. Esiri,et al.  Noradrenergic changes, aggressive behavior, and cognition in patients with dementia , 2002, Biological Psychiatry.

[44]  E. Peskind,et al.  Neurobiologic Bases of Noncognitive Behavioral Problems in Alzheimer Disease , 1994, Alzheimer disease and associated disorders.

[45]  S. Zhang,et al.  [Preliminary experimental and clinical study of the treatment of chronic renal insufficiency by granule of yi-qi bu-shen]. , 1992, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[46]  OUP accepted manuscript , 2021, Age And Ageing.

[47]  S. Comai,et al.  Tryptophan in health and disease. , 2020, Advances in clinical chemistry.

[48]  K. Lange,et al.  Effects of the noradrenergic neurotoxin DSP4 on spatial memory in the rat , 2007, Journal of neural transmission.

[49]  E. Peskind,et al.  Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. , 1997, The American journal of psychiatry.

[50]  F. Petraglia,et al.  Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type , 1992, Journal of Neural Transmission - Parkinsons Disease and Dementia Section.

[51]  H. Tohgi,et al.  Concentration of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type , 1992, Journal of neural transmission. Parkinson's disease and dementia section.